Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationMen's HealthInsulinIssue 730

AACE: Testosterone Improves Insulin Sensitivity

Testosterone supplementation has an insulin sensitizing effect in patients with diabetes.... 

Advertisement

Manav Batra, MD, of the University of Buffalo, said during a presentation, that "according to research, testosterone also increases in expression of mediators of signaling and reductions in factors that interfere." "Our data for the first time shows men with type 2 diabetes and hypogonadotropic hypogonadism are more insulin resistant as compared to men who have normal testosterone." "This hypogonadotropic hypogonadism is associated with lower expression of mediators of insulin signaling in adipose tissue as compared to men who have normal testosterone. Following the testosterone replacement in these men, the expression of mediators of insulin signaling increases, and there is a reduction in expression of mediators interfering with insulin signaling that improves insulin sensitivity."

In a randomized trial, Batra and colleagues recruited 91 men with hypogonadotropic hypogonadism (HH, n=41) and type 2 diabetes to evaluate the effect of testosterone replacement on insulin resistance.

Patients with HH were assigned testosterone (250 mg) or placebo (1 ml saline) injected intramuscularly every 2 weeks for 6 months. The researchers collected fasting blood samples, and performed fat biopsies and hyperinsulinemic euglycemic clamps, at baseline and at 6 months.

Results from the clamps showed that patients with HH have 28% lower glucose infusion rates (GIR) for a given rate of insulin infusion vs. eugonadal patients; a 30% increase in GIR was observed with testosterone treatment, consistent with a reversal of insulin resistance.

In HH adipose tissue compared to eugonadal, basal expression of mediators of insulin signaling -- including insulin resistance (IR), insulin receptor substrate (IRS-1) and glucose transporter (GLUT-4) -- was lower by 32%, 35% and 27% (P<0.05), respectively.

Following testosterone, the adipose tissue expression of IR, IRS-1 and GLUT-4 increased significantly by 63±15%, 54±17% and 59±14%, respectively, and a decrease was observed in the expression of protein-tyrosine phosphatase by 23±8% and toll-like receptor 4 by 21±11%, which interfere with insulin signaling.

Reductions were seen in several others areas that interfere with signaling, including mononuclear cells expression of suppressor of cytokine signaling-3 by 27±8% and plasma concentrations of free fatty acids and C-reactive protein by 35% and 26%, (P<0.05) respectively.

Practice Pearls:
  • Testosterone supplementation can improve insulin sensitivity in patients with diabetes.
  • Note that these studies were published as abstracts and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Batra M. Abstract 303. Presented at: AACE 23rd Annual Scientific & Clinical Congress; May 13-18, 2014; Las Vegas, Nevada. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  MedicationMen's HealthInsulinIssue 730

Past five issues: Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 | Diabetes Clinical Mastery Series Issue 223 |

2014 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
FDA Approves Weight-management Drug Saxenda
Posted December 26, 2014
Advancement in the Artificial Pancreas
Posted December 26, 2014
Type 2 Diabetes Risk Lower for Blood Type O
Posted December 26, 2014
Increased Mortality with Combining Sulfonylurea and Insulin
Posted December 26, 2014
Early Insulin Therapy Makes an Impact
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control